We recommend that you upgrade to the latest version of your browser.

MVP-Risk

While most patients with mitral valve prolapse experience a benign course with a relatively good prognosis – a subgroup of patients are characterized by a high prevalence of severe ventricular arrhythmias and elevated risk of sudden cardiac death. Risk stratification in AMVP patients is challenging and requires further validation. This research project aims to develop and validate a Risk Stratification Model for patients with individualized estimates.

On the left side of the figure, an illustration of a heart with mitral valve prolapse and various risk factors is shown. A calculator in the center of the figure illustrates how these risk factors are weighted and used to calculate an estimated 5-year risk of serious ventricular arrhythmias. The resulting risk score can be used to support clinical decision-making.

Illustration: Julie Bergh, created with assistance from OpenAI ChatGPT.

Potential risk markers in patients with mitral valve prolapse are integrated into a risk model to estimate the 5-year risk of severe ventricular arrhythmias.

MVP-Risk is a retrospective, multi-center longitudinal cohort study, including patients with MVP and arrhythmias. While several risk markers for severe ventricular arrhythmias have been identified, the weight of each marker for individual risk remains uncertain, and there is still no individualized risk estimate available. Therefore, there is a need for a risk stratification model (a risk calculator) for this patient group.

We are currently collecting data and want more collaborators. Possible collaborating centers and investigators who are interested in contributing can contact us on:
mvp-risk@ous-hf.no

ClinicalTrials.gov ID: NCT07830888

Researchers involved:

Last updated 11/9/2026